Results demonstrate statistically significant fibrosis reversal and protection against hepatocellular carcinoma in animal models of MASH –– ...

Between 1990 and 2019, cases of cancer in young people across the globe have increased by 79 percent and deaths have risen 28 ...

Life Expectancy with Stage 4 Cancer How long a person lives depends on the type of cancer. Some cancers are aggressive, have ...

Building upon a successful end-of-Phase 2 meeting, received FDA "Study May Proceed" letter for pivotal Phase 3 trial of amezalpat (TPST-1120) combination therapy to treat first-line HCCAnnounced agree ...

The FDA issued a “study may proceed” letter for the planned Phase III trial of 600mg BID amezalpat + Tecentriq+Avastin vs. Tecentriq+Avastin in 1st-line hepatocellular carcinoma. Tempest anticipates ...

The FDA approved a phase 3 trial to assess amezalpat with the current standard of care in unresectable or metastatic ...

Syros noted that SELCT-MDS-1 Phase III trial’s failure to meet its endpoint constituted a default event under its secured ...

Received a “Study May Proceed” letter from the U.S. Food and Drug Administration (FDA) to evaluate amezalpat in combination ...

The prevalence of liver steatosis was higher in people living with HIV compared with liver fibrosis, although both liver ...

(NASDAQ: ICAD) ("iCAD” or the "Company”) a global leader in clinically proven AI-powered cancer detection solutions, announced today that its ProFound Detection Version 4.0 for Digital Breast ...

HCC risk prediction may be poorly reported and biased for individuals with nonviral chronic liver disease. Hepatocellular carcinoma (HCC) risk prediction models are generally based on studies with ...